8 results about "Hematologic disorders" patented technology

Methods for administering isolated anti-CD38 antibodies subcutaneously at low doses are described. These methods provide effective treatment for autoimmune diseases and certain cancers, including hematological disorders. Unit-dose formulations for anti-CD38 antibodies are also described.

The application discloses a monoclonal antibody specifically targeting CD177 and related uses thereof, the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 in the heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO: 6-8, the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 in the light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO: 9-11, the monoclonal antibody has high affinity and specificity to CD177, can be used in the development of a high-sensitivity detection kit, helps early diagnosis of blood system diseases and autoimmune diseases, provides a reliable tool for CD177 pathological mechanism research, can lay an epitope foundation for subsequent development of therapeutic antibodies, and has outstanding clinical application value and scientific research conversion potential.

The application discloses application of CREG1 protein in preparation of medicines or reagents for inhibiting hematopoietic stem cell aging, and belongs to the field of biological medicines. The application first finds that the CREG1 protein has the function of inhibiting hematopoietic stem cell aging (including inhibiting hematopoietic stem cell proliferation abnormality, maintaining hematopoietic stem cell resting state, reducing hematopoietic stem cell DNA damage, and weakening hematopoietic stem cell myeloid differentiation tendency). Therefore, the CREG1 protein has the prospect of being developed into the medicines or reagents for inhibiting hematopoietic stem cell aging, and also has the prospect of being developed into the medicines for improving the immune function decline, anemia, bone marrow hypofunction or blood system diseases caused by hematopoietic stem cell aging.

The present disclosure relates to anti-SAA antibodies or fragments thereof, such as antibodies against human SAA1 or fragments thereof, that may be used in various therapeutic, prophylactic and diagnostic methods. The present antibodies or fragments thereof may be used to treat hematologic disorders such as acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome.

The present application relates to the field of biotechnology, in particular, the application of E4BP4 in hematological diseases such as multiple myeloma. The present application proves that E4BP4 can be used as a potential biomarker and prognostic indicator for predicting the development of multiple myeloma, which is helpful for the treatment of multiple myeloma. Moreover, the E4BP4 protein can be used in the preparation of MM promoting reagents, which can be further used in the amplification of MM cells, the preparation of MM tumor metastasis models, the screening of MM treatment drugs and the like. After knocking down E4BP4, autophagy is induced and MM cell apoptosis is promoted, thereby enhancing the anti-myeloma effect of dexamethasone on MM. E4BP4 inhibitory drugs can be used as anti-myeloma drugs together with dexamethasone.

The present disclosure provides epitopes of CD45, and binding agents such as antibodies, antibody fragments, peptides, and small molecules capable of binding to those epitopes. The present disclosure also provides methods of treating cancers, hematological diseases and disorders, and immune diseases and disorders, using these binding agents.

The invention provides a method for regulating and controlling hematopoietic balance based on a Jak2 / Stat3-Hif1a signal channel and application of the method, and belongs to the field of biotechnology and medicine. According to the method, by regulating and controlling a Jak2 / Stat3-Hif1a signal channel, hematopoietic system unbalance caused by factors such as acute inflammation or acute hypoxia is intervened or reversed. Aiming at the problems that in the prior art, mechanism cognition is not clear, intervention targets are not clear, pathway relevance research is insufficient and the like, the molecular mechanism of acute inflammation affecting hematopoietic balance is deeply explored, and the internal relation of a Jak2 / Stat3 pathway and Hif1alpha for regulating and controlling hematopoietic balance under the acute stress condition is disclosed. The invention can be applied to preparation of medicines for treating blood system diseases caused by factors such as acute inflammation and hypoxia, particularly provides a targeted intervention strategy for accurately correcting hematopoietic lineage migration aiming at diseases such as sepsis-related anemia, and has important clinical application value.

The present invention relates to the use of the proportion of plasma cells, lymphocytes or blasts expressing GLUT1 among total plasma cells, lymphocytes or blasts in a method for stratifying prognosis of subjects suffering from a hematologic disorder, and in a method for determining whether a subject suffering from a hematologic disorder will achieve or is achieving a response with a modulator of the BCL-2 family proteins. The present invention also relates to a kit for detecting GLUT1, and optionally ASCT2, for implementing one of these methods.